MOVe-AHEAD: Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Sponsor
Merck Sharp & Dohme LLC (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04939428
Collaborator
(none)
1,376
215
2
16
6.4
0.4

Study Details

Study Description

Brief Summary

The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1376 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
Actual Study Start Date :
Aug 11, 2021
Anticipated Primary Completion Date :
Dec 11, 2022
Anticipated Study Completion Date :
Dec 11, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Molnupiravir

Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.

Drug: Molnupiravir
Four molnupiravir 200 mg capsules taken by mouth.
Other Names:
  • MK-4482
  • Placebo Comparator: Placebo

    Participants take placebo Q12H on Days 1 to 5.

    Drug: Placebo
    Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.

    Outcome Measures

    Primary Outcome Measures

    1. Percentage of participants who have undetectable SARS-CoV-2 in baseline nasopharyngeal (NP) swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 [Up to Day 14]

      Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2) infection with symptoms) through Day 14.

    2. Percentage of participants with ≥1 adverse event [Up to 29 days]

      An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    3. Percentage of participants discontinuing from study therapy due to AE [Up to 5 days]

      An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Secondary Outcome Measures

    1. Percentage of participants (regardless of SARS-CoV-2 in baseline NP swabs) who develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 [Up to Day 14]

      Participants who experience targeted symptoms of COVID-19 (e.g., cough, sore throat) will have NP swabs tested for SARS-CoV-2 using reverse-transcription polymerase chain reaction (RT-PCR).

    2. Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 29 [Up to Day 29]

      Participants who experience targeted symptoms of COVID-19 (e.g., cough, sore throat) will have NP swabs tested for SARS-CoV-2 using RT-PCR.

    3. Percentage of participants who have undetectable SARS-CoV-2 in baseline NP swabs and develop detectable SARS-CoV-2 in NP swabs on or before Day 14 [Up to Day 14]

      All participants will have NP swabs collected at screening and through Day 14 to test for SARS-CoV-2 using RT-PCR.

    4. Percentage of participants who have detectable SARS-CoV-2 in baseline NP swabs and develop COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms) through Day 14 [Up to Day 14]

      Participants who experience targeted symptoms of COVID-19 (e.g., cough, sore throat) will have NP swabs tested for SARS-CoV-2 using RT-PCR.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Lives in a household with an index case where the index case is a person with documented COVID-19 (laboratory-confirmed SARS-CoV-2 infection with symptoms case) and must have 1) a first detectable SARS-CoV-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to COVID-19 (e.g., fever, difficulty breathing)

    • Does not have confirmed or suspected COVID-19

    • Is willing and able to take oral medication

    • For males, agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective contraceptive method while receiving study drug and for ≥3 months after the last dose of study drug

    • Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method), or is a WOCBP who is abstinent from heterosexual intercourse

    Exclusion Criteria:
    • Has a prior history of laboratory-confirmed SARS-CoV-2 infection (with or without symptoms) within 6 months prior to randomization

    • Has either of the following: human immunodeficiency virus (HIV) with a recent viral load >50 copies/mL (regardless of CD4 count) or an acquired immunodeficiency syndrome (AIDS)-defining illness

    • Has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (AST) and/or (ALT) >3x upper limit of normal at screening

    • Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator

    • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents

    • Has received, is taking, or is anticipated to require any prohibited therapies

    • Has received a COVID-19 vaccination with the first dose ≥7 days prior to randomization

    • Is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics

    • Is living in a household with >10 people

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cahaba Research, Inc. ( Site 2523) Birmingham Alabama United States 35235
    2 The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2484) Mesa Arizona United States 85210
    3 The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2448) Tucson Arizona United States 85712
    4 Hope Clinical Research ( Site 2400) Canoga Park California United States 91303
    5 Carbon Health ( Site 2515) Carlsbad California United States 92009
    6 UCSF Fresno ( Site 2528) Fresno California United States 93701
    7 ASCADA Research, LLC ( Site 2516) Fullerton California United States 92835
    8 Marvel Clinical Research ( Site 2490) Huntington Beach California United States 92647
    9 National Research Institute ( Site 2452) Los Angeles California United States 90057
    10 Valley Clinical Trials Inc. ( Site 2406) Northridge California United States 91325
    11 Carbon Health ( Site 2514) Oakland California United States 94610
    12 University of California Davis ( Site 2497) Sacramento California United States 95817
    13 Millennium Clinical Trials ( Site 2468) Simi Valley California United States 93065
    14 Future Innovative Treatments, LLC ( Site 2471) Colorado Springs Colorado United States 80907
    15 Emerson Clinical Research Institute ( Site 2457) Washington District of Columbia United States 20011
    16 Synergy Healthcare ( Site 2521) Bradenton Florida United States 34208
    17 Accel Research Sites-DeLand Clinical Research Unit ( Site 2535) DeLand Florida United States 32720
    18 Velocity Clinical Research, Hallandale Beach ( Site 2485) Hallandale Beach Florida United States 33009
    19 Indago Research and Health Center Inc ( Site 2412) Hialeah Florida United States 33012
    20 Advanced Research For Health Improvement LLC ( Site 2436) Immokalee Florida United States 34142
    21 Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508) Miami Florida United States 33186
    22 Clinical Research Trials of Florida ( Site 2402) Tampa Florida United States 33607
    23 Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2425) Winter Park Florida United States 32789
    24 Chicago Clinical Research Institute Inc ( Site 2454) Chicago Illinois United States 60607
    25 Rush University Medical Center ( Site 2510) Chicago Illinois United States 60612
    26 MedPharmics, LLC ( Site 2443) Metairie Louisiana United States 70006
    27 Institute of Human Virology ( Site 2504) Baltimore Maryland United States 21201
    28 Centennial Medical Group ( Site 2435) Elkridge Maryland United States 21075
    29 Jadestone Clinical Research, LLC ( Site 2530) Silver Spring Maryland United States 20904
    30 Michigan Center of Medical Research ( Site 2445) Farmington Hills Michigan United States 48334
    31 Michigan Center of Medical Research ( Site 2525) Lathrup Village Michigan United States 48076
    32 Allina Health Infectious Diseases Research Clinic ( Site 2507) Minneapolis Minnesota United States 55404
    33 University of Missouri Hospital ( Site 2486) Columbia Missouri United States 65212
    34 Mercury Street Medical Group PLLC ( Site 2476) Butte Montana United States 59701
    35 University of Nebraska Medical Center ( Site 2430) Omaha Nebraska United States 68198-3135
    36 Excel Clinical Research, LLC ( Site 2404) Las Vegas Nevada United States 89109
    37 ID Care ( Site 2466) Hillsborough New Jersey United States 08844
    38 Amici Clinical Research LLC ( Site 2426) Raritan New Jersey United States 08869
    39 AXCES Research Group ( Site 2437) Santa Fe New Mexico United States 87505
    40 Montefiore Medical Center ( Site 2503) Bronx New York United States 10462
    41 ECU Adult Specialty Care ( Site 2415) Greenville North Carolina United States 27834
    42 The Lindner Center for Research and Education at The Christ Hospital ( Site 2517) Cincinnati Ohio United States 45219
    43 Dayton Clinical Research ( Site 2488) Dayton Ohio United States 45406
    44 Cherokee Nation WW Hastings Indian Hospital/Cherokee Nation Health Services ( Site 2459) Tahlequah Oklahoma United States 74464
    45 Preferred Clinical Research ( Site 2470) Pittsburgh Pennsylvania United States 15236
    46 Velocity Clinical Research-Providence ( Site 2432) East Greenwich Rhode Island United States 02818
    47 Tribe Clinical Research, LLC ( Site 2409) Greenville South Carolina United States 29607
    48 TTS Research ( Site 2433) Boerne Texas United States 78006
    49 Houston Methodist Hospital ( Site 2463) Houston Texas United States 77030
    50 Santa Clara Family Clinic ( Site 2462) Houston Texas United States 77087
    51 Crossroads Clinical Research LLC ( Site 2451) Victoria Texas United States 77901
    52 TPMG Clinical Research ( Site 2495) Williamsburg Virginia United States 23188
    53 Covid-19 Clinical Research Center (CCRC) ( Site 2421) Seattle Washington United States 98109
    54 Sanatorio de la Trinidad Mitre ( Site 0108) Caba Buenos Aires Argentina C1039AAO
    55 Mautalen Salud e Investigacion ( Site 0103) Caba Buenos Aires Argentina C1128AAF
    56 Hospital Italiano de Buenos Aires ( Site 0102) Caba Buenos Aires Argentina C1199ABB
    57 Instituto de Investigaciones Clínicas Mar del Plata ( Site 0105) Mar del Plata Buenos Aires Argentina B7600FZO
    58 Clinica Independencia ( Site 0104) Munro Buenos Aires Argentina B1605FRE
    59 Grupo Oroño Centro medico San Nicolas ( Site 0109) San Nicolas Buenos Aires Argentina B2900DPA
    60 Instituto Medico de la Fundacion Estudios Clinicos ( Site 0106) Rosario Santa Fe Argentina 2000
    61 CEMIC ( Site 0101) Buenos Aires Argentina C1431FWO
    62 Fundaçao de Medicina Tropical Doutor Heitor Vieira Dourado ( Site 0303) Manaus Amazonas Brazil 69040-000
    63 Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS ( Site 0305) Campo Grande Mato Grosso Do Sul Brazil 79070-900
    64 Hospital Nossa Senhora das Gracas ( Site 0310) Curitiba Parana Brazil 80810-040
    65 Oncosite-Centro de Pesquisa Clinica em Oncologia ( Site 0300) Ijui Rio Grande Do Sul Brazil 98700-000
    66 Centro de Referência e Treinamento DST/AIDS ( Site 0301) Sao Paoulo Sao Paulo Brazil 04121-000
    67 Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0312) São José do Rio Preto Sao Paulo Brazil 15090000
    68 Centro de Referencia Professor Helio Fraga - FIOCRUZ/RJ ( Site 0314) Rio de Janeiro Brazil 22780-192
    69 Medical Center Hera EOOD ( Site 3001) Sofia Sofia (stolitsa) Bulgaria 1510
    70 Medical Center Hera Kyustendi EOOD ( Site 3003) Kyustendil Bulgaria 2500
    71 Medical Center Hera EOOD - Montana branch ( Site 3002) Montana Bulgaria 3400
    72 Fundacion Centro de Investigacion Clinica CIC ( Site 0402) Medellin Antioquia Colombia 050021
    73 Centro Cientifico Asistencial Jose Luis Accini ( Site 0412) Barranquilla Atlantico Colombia 080020
    74 Clinica de la Costa Ltda. ( Site 0407) Barranquilla Atlantico Colombia 080020
    75 Oncomedica S.A. ( Site 0406) Monteria Cordoba Colombia 230002
    76 Hospital Universitario Clinica San Rafael ( Site 0410) Bogota Cundinamarca Colombia 110411
    77 Healthy Medical Center S.A.S ( Site 0413) Zipaquira Cundinamarca Colombia 250252
    78 Caja de Compensacion Familiar CAFAM ( Site 0403) Bogota Distrito Capital De Bogota Colombia 111211
    79 Fundacion Centro de Investigaciones Clinicas CARDIOMET ( Site 0409) Pereira Risaralda Colombia 660003
    80 Instituto Neumologico del Oriente S.A. ( Site 0408) Bucaramanga Santander Colombia 681004
    81 Fundacion Valle del Lili ( Site 0405) Cali Valle Del Cauca Colombia 760032
    82 Unidad de Aislamiento del Centro de Obstetricia y Ginecologia ( Site 2650) Santo Domingo Distrito Nacional Dominican Republic 10605
    83 National Center for allergies and chest ( Site 2940) Giza Al Jizah Egypt 12651
    84 Imbaba Fevers Hospital ( Site 2945) Giza Al Jizah Egypt 12661
    85 Masri - CRC - Ain Shams University ( Site 2900) Cairo Al Qahirah Egypt 11566
    86 Masri - CRC - Ain Shams University ( Site 2910) Cairo Al Qahirah Egypt 11566
    87 National Hepatology and Tropical Medicine Research Institute ( Site 2930) Cairo Al Qahirah Egypt 11796
    88 Air Force Specialized Hospital Clinical Research Center ( Site 2920) Cairo Al Qahirah Egypt 11835
    89 Maison de Sante Universitaire La Providence ( Site 0506) Toulouse Haute-Garonne France 31500
    90 Hôpital Pitié - Salpêtrière ( Site 0501) Paris Ile-de-France France 75013
    91 CHU de la Reunion - Groupe Hospitalier Sud ( Site 0508) Saint Pierre Cedex La Reunion France 97448
    92 CHU Martinique ( Site 0511) Fort De France Martinique France 97200
    93 Maison de santé du Pays Neufchatelois ( Site 0507) Neufchatel-en-Bray Seine-Maritime France 76270
    94 Centro de Investigaciones Pediatricas ( Site 0703) Guatemala Guatemala 01001
    95 Unidad de Diagnostico Cardiologico ( Site 0701) Guatemala Guatemala 01001
    96 Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 0702) Guatemala Guatemala 01009
    97 Clinica Privada ( Site 0705) Guatemala Guatemala 01010
    98 Private Clinic - Dr. Hugo Pezzarossi ( Site 0704) Guatemala Guatemala 01015
    99 LONA MEDIC Kft ( Site 0804) Oroshaza Bekes Hungary 5900
    100 Debreceni Egyetem Klinikai Kozpont- Infektologiai Klinika ( Site 0824) Debrecen Hajdu-Bihar Hungary 4031
    101 Bugat Pal Korhaz ( Site 0817) Gyongyos Heves Hungary 3200
    102 Medifarma-98 Kft. ( Site 0808) Nyiregyhaza Szabolcs-Szatmar-Bereg Hungary 4400
    103 DRC Gyogyszervizsgalo Kozpont Kft. ( Site 0801) Balatonfured Veszprem Hungary 8230
    104 Obudai Egeszsegugyi Centrum - OEC ( Site 0821) Budapest Hungary 1036
    105 Strazsahegy Medicina Bt ( Site 0823) Budapest Hungary 1171
    106 Obudai Egeszsegugyi Centrum - Zalaegerszeg ( Site 0819) Zalaegerszeg Hungary 8900
    107 IUHW Narita Hospital ( Site 1105) Narita Chiba Japan 286-8520
    108 National Hospital Organization Okinawa National Hospital ( Site 1109) Ginowan Okinawa Japan 901-2214
    109 Social Medical Corporation Yuuaikai Yuuai Medical Center ( Site 1108) Tomigusuku Okinawa Japan 901-0224
    110 Chiba Aoba Municipal Hospital ( Site 1100) Chiba Japan 260-0852
    111 Global Healthcare Clinic ( Site 1106) Tokyo Japan 102-0083
    112 Den-en-chofu family clinic ( Site 1104) Tokyo Japan 145-0071
    113 Center Hospital of the National Center for Global Health and Medicine ( Site 1101) Tokyo Japan 162-8655
    114 KEMRI-CMR-RCTP- Kenya Medical Research Institute Kisumu ( Site 1925) Kisumu Kenya 40100
    115 Hospital Raja Perempuan Zainab II ( Site 2851) Kota Bharu Kelantan Malaysia 15586
    116 Klinik Kesihatan Masjid Tanah ( Site 2850) Masjid Tanah Melaka Malaysia 78300
    117 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 1308) Ciudad de Mexico Distrito Federal Mexico 14080
    118 Morales Vargas Centro de Investigacion, S.C. ( Site 1318) Leon Guanajuato Mexico 37000
    119 Hospital General de Acapulco ( Site 1319) Acapulco Guerrero Mexico 39570
    120 Instituto Jalisciense de Metabolismo SC ( Site 1314) Guadalajara Jalisco Mexico 44670
    121 Centro Médico Universitario ( Site 1316) Cuernavaca Morelos Mexico 62210
    122 CHRISTUS - LATAM HUB CENTER OF EXCELLENCE AND INNOVATION S.C. ( Site 1315) Gral Escobedo Nuevo Leon Mexico 66055
    123 Centro de Investigacion y Avances Medicos Especializados -CIAME ( Site 1301) Cancun Quintana Roo Mexico 77500
    124 Köhler & Milstein Research S.A. de C.V. ( Site 1300) Merida Yucatan Mexico 97070
    125 Centro de Investigacion Medica Aguascalientes ( Site 1305) Aguascalientes Mexico 20116
    126 ICARO Investigaciones en Medicina ( Site 1313) Chihuahua Mexico 31000
    127 Medica Sur S.A.B de C.V. ( Site 1303) Mexico City Mexico 14050
    128 Oaxaca Site Management Organization S.C. ( Site 1304) Oaxaca Mexico 68000
    129 Arké SMO S.A de C.V ( Site 1306) Veracruz Mexico 91910
    130 Policlínico Especializado en Neurología - Unid. Inv. Neurológica ( Site 1403) La Perla Qallaw Peru 07011
    131 Clínica Ricardo Palma ( Site 1406) Lima Peru 15036
    132 Asociacion Civil por la Salud ( Site 1411) Lima Peru 15046
    133 Investigaciones Medicas en Salud - INMENSA ( Site 1401) Lima Peru 15046
    134 Asociacion Civil IMPACTA Salud y Educacion - Sede San Miguel ( Site 1410) Lima Peru 15088
    135 Clinica Providencia ( Site 1400) Lima Peru 15088
    136 Instituto de Investigacion Nutricional - Anexo Huascar ( Site 1404) Lima Peru 15423
    137 Asian Hospital and Medical Center ( Site 1503) Muntinlupa National Capital Region Philippines 1780
    138 Quirino Memorial Medical Center ( Site 1501) Quezon City National Capital Region Philippines 1109
    139 Centrul Medical Unirea SRL Bucuresti ( Site 1706) Bucaresti Bucuresti Romania 011601
    140 Centrul Medical Unirea SRL ( Site 1707) Cluj-Napoca Cluj Romania 400349
    141 S.C Materna Care SRL ( Site 1702) Timisoara Timis Romania 300645
    142 Centrul Medical Unirea ( Site 1705) Brasov Romania 500091
    143 Delta Heath Care S.R.L ( Site 1708) Bucuresti Romania 014142
    144 SC Policlinica CCBR SRL. Bucuresti ( Site 1704) Bucuresti Romania 030463
    145 Centrul Medical Unirea SRL Constanta ( Site 1703) Constanta Romania 900540
    146 Centrul Medical Unirea SRL IASI ( Site 1701) Iasi Romania 700023
    147 FSBI Central Hospital with Policlinics ( Site 1807) Moscow Moskva Russian Federation 121359
    148 Infectious Clinical Hospital # 1 ( Site 1834) Moscow Moskva Russian Federation 125310
    149 SPb SBHI City outpatient clinic 112 ( Site 1829) Saint Petersburg Sankt-Peterburg Russian Federation 195427
    150 Smorodintsev Research Institute of Influenza ( Site 1833) Saint Petersburg Sankt-Peterburg Russian Federation 197376
    151 Nikolaevskaya hospital ( Site 1810) Saint Petersburg Sankt-Peterburg Russian Federation 198510
    152 SPb SBHI City outpatient clinic 4 ( Site 1831) Saint Petersburg Sankt-Peterburg Russian Federation 199406
    153 Limited liability company "Scientific research center Eco-safety" ( Site 1809) Saint-Petersburg Sankt-Peterburg Russian Federation 196143
    154 City Polyclinic #88 ( Site 1808) Saint-Petersburg Sankt-Peterburg Russian Federation 198261
    155 LLC -Medical Center . Capital-Polis ( Site 1825) Saint-Petrsburg Sankt-Peterburg Russian Federation 190013
    156 St.Petersburg Outpatient Clinic No. 109 ( Site 1818) Saint-Petrsburg Sankt-Peterburg Russian Federation 192289
    157 SPb SBHI. City outpatient clinic No.44 ( Site 1830) St.Petersburg Sankt-Peterburg Russian Federation 192071
    158 Medical Research Institute LLC. ( Site 1814) St.Petersburg Sankt-Peterburg Russian Federation 196084
    159 Smolensk State Medical University ( Site 1803) Smolensk Smolenskaya Oblast Russian Federation 214019
    160 Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1802) Kazan Tatarstan, Respublika Russian Federation 420140
    161 Voronezh Regional Clinical Hospital #1 ( Site 1823) Voronezh Voronezskaja Oblast Russian Federation 394066
    162 LLC -Clinic of modern medicine of Doctor Bogorodskaya ( Site 1828) Yaroslavl Yaroslavskaya Oblast Russian Federation 150001
    163 IATROS International ( Site 1921) Bloemfontein Free State South Africa 9300
    164 REIMED Reiger Park ( Site 1910) Boksburg Gauteng South Africa 1459
    165 Midrand Medical Centre ( Site 1913) Halfway House, Midrand Gauteng South Africa 1685
    166 Wits Health Consortium. Clinical HIV Research Unit ( Site 1923) Johannesburg Gauteng South Africa 2041
    167 Right To Care Research - Esizayo ( Site 1907) Johannesburg Gauteng South Africa 2087
    168 DJW Navorsing ( Site 1915) Krugersdorp Gauteng South Africa 1739
    169 Mzansi Ethical Research Centre ( Site 1918) Mpumalanga Gauteng South Africa 1055
    170 Jongaie Research ( Site 1900) Pretoria-West Gauteng South Africa 0183
    171 Global Clinical Trial Centre ( Site 1904) Pretoria Gauteng South Africa 0186
    172 Dr Jugnundun & Partners ( Site 1905) Durban Kwazulu-Natal South Africa 4091
    173 Enhancing Care Foundation-DICRS ( Site 1922) Durban Kwazulu-Natal South Africa 4091
    174 Private Practice - Dr. Neyaseelan Gounden ( Site 1911) Durban Kwazulu-Natal South Africa 4093
    175 Limpopo Clinical Research Initiative ( Site 1901) Thabazimbi Limpopo South Africa 0380
    176 TASK Applied Science ( Site 1920) Cape Town Western Cape South Africa 7405
    177 DTHF Masiphumelele Clinical Research Site ( Site 1919) Cape Town Western Cape South Africa 7975
    178 Be Part Yoluntu Centre ( Site 1914) Paarl Western Cape South Africa 7626
    179 Paarl Research Centre ( Site 1924) Paarl Western Cape South Africa 7646
    180 Hospital Universitari Germans Trias i Pujol ( Site 2010) Badalona Barcelona Spain 08916
    181 CAP Centelles ( Site 2011) Centelles Barcelona Spain 08540
    182 Hospital de Alcorcon ( Site 2003) Alcorcon Madrid, Comunidad De Spain 28922
    183 C.S. Vallcarca-Sant Gervasi ( Site 2000) Barcelona Spain 08023
    184 CAP de Sardenya ( Site 2009) Barcelona Spain 08025
    185 Hospital Universitario Infanta Leonor ( Site 2002) Madrid Spain 28031
    186 Hospital Universitario La Paz ( Site 2024) Madrid Spain 28046
    187 HIV-NAT AIDS Research Centre ( Site 2804) Bangkok Krung Thep Maha Nakhon Thailand 10330
    188 Chulabhorn Hospital ( Site 2801) Lak Si Krung Thep Maha Nakhon Thailand 10210
    189 Rajavithi Hospital ( Site 2803) Ratchathewi Krung Thep Maha Nakhon Thailand 10400
    190 The Golden Jubilee Medical Center ( Site 2800) Phutthamonthon Nakhon Pathom Thailand 73170
    191 Songklanagarind Hospital ( Site 2802) Hat-Yai Songkhla Thailand 90110
    192 Atakent Acibadem Hastanesi ( Site 2103) Halkali/K.cekmece Istanbul Turkey 34303
    193 Sancaktepe Prof Dr Ilhan Varank EAH-Prof Dr Feriha Oz Hastanesi ( Site 2113) Istabul Istanbul Turkey 34785
    194 Ankara Universitesi Ibni Sina Hastanesi ( Site 2101) Ankara Turkey 06230
    195 Hacettepe Universitesi Tip Fakultesi ( Site 2102) Ankara Turkey 06230
    196 Gazi Universitesi Tip Fakultesi Hastanesi ( Site 2106) Ankara Turkey 06560
    197 Ankara Sehir Hastanesi ( Site 2111) Ankara Turkey 06800
    198 Istanbul Universitesi Istanbul Tip Fakultesi ( Site 2110) Istanbul Turkey 34093
    199 Medipol Universite Hastanesi ( Site 2108) Istanbul Turkey 34214
    200 Basaksehir Cam ve Sakura City Hospital ( Site 2112) Istanbul Turkey 34494
    201 Ege Universitesi Tip Fakultesi Hastanesi ( Site 2105) Izmir Turkey 35100
    202 Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2107) Sakarya Turkey 54100
    203 Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 2232) Ivano-Frankivsk Ivano-Frankivska Oblast Ukraine 76007
    204 Regional Phthisiopulmonological Center ( Site 2203) Ivano-Frankivsk Ivano-Frankivska Oblast Ukraine 76018
    205 NPME -Central Clinical Hospital of Ivano-Frankivsk City Council ( Site 2204) Ivano-Frankivsk Ivano-Frankivska Oblast Ukraine 76025
    206 Non profit municipal enterprise City hospital student of Kharkiv city council ( Site 2229) Kharkiv Kharkivska Oblast Ukraine 61002
    207 PCNE Kharkiv City polyclinic 9 of the Kharkiv City Council ( Site 2201) Kharkiv Kharkivska Oblast Ukraine 61172
    208 Limited Liability Company Medical center Healthy Happy ( Site 2225) Kyiv Kyivska Oblast Ukraine 01033
    209 MNPE Consultative-Diagnostic Centre of Desnyanskyi District of Kyiv ( Site 2205) Kyiv Kyivska Oblast Ukraine 02232
    210 Kyiv railway clinical hospital 2 of Branch Health center ( Site 2207) Kyiv Kyivska Oblast Ukraine 03049
    211 Municipal Noncommercial Enterprise Lviv 4th City Clinical Hospital ( Site 2200) Lviv Lvivska Oblast Ukraine 79011
    212 Odesa Regional Center of Socially Significant Diseases ( Site 2230) Odesa Odeska Oblast Ukraine 65014
    213 MNCE -Odesa regional clinical hospital of Odesa regional council ( Site 2226) Odessa Odeska Oblast Ukraine 65025
    214 Municipal Enterprise Poltava Regional Clinical Infectious Hospital ( Site 2227) Poltava Poltavska Oblast Ukraine 36011
    215 Medical Clinical Investigational Center of Medical Center Health Clinic ( Site 2210) Vinnytsia Vinnytska Oblast Ukraine 21009

    Sponsors and Collaborators

    • Merck Sharp & Dohme LLC

    Investigators

    • Study Director: Medical Director, Merck Sharp & Dohme LLC

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Merck Sharp & Dohme LLC
    ClinicalTrials.gov Identifier:
    NCT04939428
    Other Study ID Numbers:
    • 4482-013
    • MK-4482-013
    • jRCT2031210281
    • PHRR211007-003980
    • 2021-000904-39
    First Posted:
    Jun 25, 2021
    Last Update Posted:
    Aug 12, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 12, 2022